These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8963784)

  • 21. [An attempt to prevent lymphoid atrophy in secondary disease of radiation chimeras by means of transplanting the lymphocytes of a recipient].
    Koval'chuk LV; Zaretskaia IuM
    Biull Eksp Biol Med; 1967 Oct; 63(10):82. PubMed ID: 4914553
    [No Abstract]   [Full Text] [Related]  

  • 22. Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells.
    Cornetta K; Gharpure V; Mills B; Hromas R; Abonour R; Broun ER; Traycoff CM; Hanna M; Wyman N; Danielson C; Gonin R; Kunkel LK; Oldham F; Srour EF
    Bone Marrow Transplant; 1998 Jan; 21(1):65-71. PubMed ID: 9486497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppressive agents.
    Dannie E
    Nurs Times; 1993 Jan 27-Feb 2; 89(4):34-7. PubMed ID: 8437902
    [No Abstract]   [Full Text] [Related]  

  • 29. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
    Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Allogenic bone marrow transplantation complications. Part II].
    Saloua L; Tarek BO; Abderrahman A; Abdeladhim BA
    Tunis Med; 2000 Mar; 78(3):152-7. PubMed ID: 11026816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of graft-versus-host disease by naturally occurring regulatory T cells.
    Zeng D; Lan F; Hoffmann P; Strober S
    Transplantation; 2004 Jan; 77(1 Suppl):S9-S11. PubMed ID: 14726761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
    Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
    Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model.
    Vogelsang GB; Wells MC; Santos GW; Chen TL; Hess AD
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of acquired a plastic anemia: an update].
    Kojima S
    Rinsho Ketsueki; 2004 Mar; 45(3):202-8. PubMed ID: 15103933
    [No Abstract]   [Full Text] [Related]  

  • 38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.